{"disease":{"id":"focal-onset-seizures","name":"focal onset seizures"},"drugs":{"marketed":[{"drug_id":"xcopri","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xcopri","company_name":"SK Life Science, Inc.","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4, Gamma-aminobutyric acid receptor subunit alpha-6","drug_class":"","quality_score":16,"revenue":null,"mechanism":null},{"drug_id":"cenobamate","indication_name":"Epilepsy having focal-onset seizures","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xcopri","generic_name":"CENOBAMATE","company_name":"Sk Life","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-4","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Xcopri works by enhancing the activity of a neurotransmitter called GABA, which helps calm down abnormal electrical activity in the brain."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03373383","title":"Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"UCB Biopharma S.P.R.L.","has_results":true},{"nct_id":"NCT03370120","title":"Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":406,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT05614063","title":"A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":380,"lead_sponsor_name":"Xenon Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03739840","title":"A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":232,"lead_sponsor_name":"UCB Biopharma SRL","has_results":true},{"nct_id":"NCT06922175","title":"REACH: RWE Retrospective Study to Evaluate Cenobamate Impact on Health Care Resource Utilization","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Aziende Chimiche Riunite Angelini Francesco S.p.A","has_results":false},{"nct_id":"NCT04836559","title":"A Study to Investigate JNJ-40411813 in Combination With Levetiracetam or Brivaracetam in Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":true},{"nct_id":"NCT07141329","title":"SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Supernus Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06377930","title":"Study Evaluating the Safety and Efficacy of RAP-219 in Adult Participants With Refractory Focal Epilepsy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":30,"lead_sponsor_name":"Rapport Therapeutics Inc.","has_results":false},{"nct_id":"NCT05473442","title":"Study of EQU-001 for Uncontrolled Focal Onset Seizures","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Equilibre Biopharmaceuticals B.V.","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}